Summit Therapeutics to stop developing muscle-wasting disorder drug

(Reuters) - Summit Therapeutics Plc said on Wednesday that it would stop developing its Duchenne muscular dystrophy (DMD) drug after it failed to meet the goals of a mid-stage study.